Kyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar Antibody

BOSTON, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kyungdong Pharmaceutical announced that it has successfully completed a cell line development campaign for a biosimilar antibody candidate, in collaboration with Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development. Through this collaboration, Kyungdong secured a high-performing production cell line for its next-generation biosimilar antibody candidate, laying the foundation for process development, large-scale manufacturing, and eventual commercialization.